Homocysteine and cystatin C level changes in haemodialysed patients and connection with cerebro- and cardiovascular complications

Acta Physiologica Hungarica

Volumn 88, Issue 3-4, 2001, Pages 293-299

  Locsey, Lajos ^a   Szegedi, J ^b   Dán, Anikó ^c   Gorogh S ^d   Tóth, Eszter ^e  

^a EuroCare 10 Dialysis Center Debrecen   (Hungary)

^b Jósa András Hospital I   (Hungary)

^c Central Laboratory   (Hungary)

^d Artificial Kidney Department EuroCare 12   (Hungary)

^e Békéscsabai Hospital I   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATIN; CYSTATIN C; HOMOCYSTEINE;

ADOLESCENT; ADULT; AGED; ARTERIOSCLEROSIS; ARTICLE; BLOOD; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTERIOSCLEROSIS; CEREBROVASCULAR ACCIDENT; CYSTATINS; DIABETES MELLITUS, TYPE 1; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 0035552378     PISSN: 0231424X     EISSN: None     Source Type: Journal    
DOI: 10.1556/APhysiol.88.2001.3-4.11     Document Type: Article

References (22)

1. House AA, Wells GA, Donelly JG, Nadler SP, Hébert PC: Randomised trial of high-flux vs. Low-flux haemodialysis: effects on homocysteine and lipids. Nephrol. Dial.Transpl. 15, 1029-1034 (2000)
2. Massy ZA: Reversal of hyperhomocysteinaemia in chronic renal failure - is folic acid the answer? Nephrol. Dial. Transpl. 14, 2810-2812 (1999)
3. Bostom AG, Culleton BF: Hyperhomocysteinaemia in chronic renal disease. J. Am. Soc. Nephrol. 10, 891-900 (1999)
4. Robinson K, Gupta A, Dennis V: Hyperhomocysteinaemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94, 2743-2748 (1996)
5. Bostom AG, Gohn RY, Bausserman L, Hakas D, Jacques PF, Selhub J, Dworkin L, Rosenberg IH: Serum Cystatin C as a determinant of fasting total homocysteine levels in renal transplant recipients with a normal serum creatinine. J. Am. Soc. Nephrol. 10, 164-166 (1999)
6. Khyse AJ, Schmidt C, Nordin G, Anderson B, Nilsson EP, Lindstrom V: Serum Cystatin C determined by a rapid automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin. Chem. 40, 1921-1926 (1994)
7. Plebani M Dall, Amico R, Mussap M, Monitini G, Ruzzante N, Marsilio R, Giordano G: Is serum Cystatin C a sensitive marker of glomerular filtration rate (GFR)? A preliminary study on renal transplant patients. Renal Failure 20, 303-309 (1998)
8. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH: Vitamin status and intake as primary determination of homocysteinaemia in an elderly population. JAMA 270, 2693-2698 (1993)
9. Bostom AG, Lathrop: Hyperhomocysteinaemia in end-stage disease. Prevalence, etiology and potential relationship to arteriosclerotic outcomes. Kidney Int. 52, 10-20 (1997)
10. Norlund L, Grubb A, Fex G, Leksell H, Nilsson JE, Schenk H: The increase of plasma homocysteine concentrations with age is partly due to the deterioration of renal function as determined by plasma Cystatin. C. J. Clin. Chem. Lab. Med. 36, 175-178 (1998)
11. Bostom AG: Homocysteine: "expensive Creatinine" or important, modifiable risk factor for arteriosclerotic outcomes in renal transplant recipients? J. Am. Soc. Nephrol. 11, 149-151 (2000)
12. Bostom AG, Selhub J: Homocysteine and arteriosclerosis: Subclinical and clinical disease associations. Circulation 99, 2361-2363 (1999)
13. Clarke R, Collins R: Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the Homocysteine hypothesis of vascular disease. J. Cardiovascular. Risk 5, 249-255 (1998)
14. Rosenthal AF, Ginsburg MJ, Crawford JF: Homocysteine and heart disease in dialysis patients. Dialysis Transplant. 27, 627-629 (1998)
15. Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J: Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. Arterioscler. Thromb. Vasc. Biol. 11, 2554-2558 (1997)
16. Suliman ME, Anderstam B, Lindholm B, Bergström J: Total-, free and protein-bound sulphur amino acids in uraemic patients. Nephrol. Dial. Transpl. 12, 2332-2338 (1997)
17. Jacques PF, Selhub J, Rosenberg H: Hyperhomocysteinaemia, hyperfibrinogenaemia, and lipoprotein excess in maintenance dialysis patients: A matched case-control study. Atherosclerosis 125, 91-101 (1996)
18. Gupta A, Robinson K: Hyperhomocysteinaemia and end-stage renal disease. J. Nephrol. 10, 77-84 (1997)
19. Tamura T, Johnston J: Homocysteine and folate concentrations in blood from patients treated with haemodialysis. J. Am. Soc. Nephrol. 7, 2414-2418 (1996)
20. Ubbink JB: The role of vitamins in the pathogenesis and treatment of hyperhomocysteinaemia. J. Intern. Metab. Dis. 20, 316-325 (1997)
21. Aukrust P, Berge RK, Muller F, Ueland PM, Svardal AM, Froland SS: Elevated plasma levels of reduced homocysteine in common variable Immunodeficiency: A marker of enhanced oxidative stress. Eur. J. Clin. Invest. 27, 723-730 (1997)
22. Ducloux D, Motte G, Charlier B, Gibey R, Chalopin JM: Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J. Am. Soc. Nephrol. 11, 134-137 (2000)